Primaquine radical cure of Plasmodium vivax malaria: a risk-benefit analysis

伯氨喹根治间日疟原虫疟疾：风险效益分析

• 批准号: nhmrc : GNT1115347
• 负责人: Dr Robert Commons
• 金额: $ 8.18万
• 依托单位: Menzies School of Health Research
• 依托单位国家: 澳大利亚
• 项目类别: Postgraduate Scholarships
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/primaquine-radical-cure-benefit-analysis/1346952
• 关键词: Primaquine; radical; cure; Plasmodium; vivax

Vivax malaria causes significant morbidity with over 100 million clinical cases each year and can cause a relapsing illness and chronic anaemia. The only available radical cure of P. vivax requires administration of primaquine, which can cause severe haemolysis in some patients. Our research aims to determine the risks and benefits of giving primaquine to cure vivax malaria using data from meta-analyses of published clinical trials and individual patient results from large multicentre trials.

间日疟造成重大发病率，每年临床病例超过1亿例，并可导致复发性疾病和慢性贫血。唯一可用的根治间日疟原虫的方法是使用伯氨喹，这会在一些患者中导致严重的溶血。我们的研究旨在利用已发表的临床试验的荟萃分析数据和大型多中心试验的个体患者结果来确定给予伯氨喹治疗间日疟的风险和好处。